Research Article

Molecular Profiling of Breast Cancer Susceptibility of Obese or Insulin-Resistant and Pre-Diabetic Patients Using *ITLN1* and *CD295* SNPs

Nadia M. Hamdy^{1*} and Reham A. El-Shemy²

¹ Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Abassia, 11566, Cairo, Egypt, ² Department of Clinical Pathology, National Cancer Institute, Cairo University, Egypt

*Corresponding author: Dr. Nadia M. Hamdy, Prof. of Biochemistry, Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Abassia, Monazamat Al-Wahda Al-Afriqia st., 11566, Cairo, Egypt. Email: nadia_hamdy@pharma.asu.edu.eg

Running head: Inflammation/obesity genes SNPs & DNA damage in BC.

Remarks/Highlights.

- *ITLN1* and *CD295* polymorphism testing might be utilized for accessing BC susceptibility in either obese or insulin resistant, pre-diabetic patients.
- A modestly increased risk of BC in women harboring the C allele of *CD295* rs6700986 polymorphism and the T allele of the *ITLN1* rs952804, where:
  - 1- Tumor clinical stage T II and positive LN involvement as well as the tumor histologic grade III, obesity existence, pre-diabetic event and being diabetic as well as IR cases were associated with *CD295* rs6700986 mutant homozygous (CC) and heterozygous (CT) genotype and *ITLN1* rs952804 mutant heterozygous cases (CT) ($P \leq 0.05$).
  - 2- Tail DNA (%) and tail moment unit were significantly associated with *CD295* rs6700986 CT genotype and *ITLN1* rs952804 TT. These SNPs could be considered as BC associated risk factor.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 26 • In dominant effect of the C allele (CT+CC vs TT) and the T allele (TT+CT vs CC)
- 27 for *CD295* rs6700986 and *ITLN1* rs952804, respectively, were associated with BC
- 28 events and risk ($P \leq 0.05$).
- 29 • *CD295* rs6700986 and *ITLN1* rs952804 SNPs may be considered BC-associated
- 30 risk for G3, T2, +LN, obesity, pre-diabetic/diabetic and IR in BC patients.

31

32 **Abstract:**

33 Mutations in cluster of differentiation (CD) 295 gene, encoding class I cytokine
 34 receptor, are associated with obesity and breast cancer (BC). SNPs in the adipocyte-
 35 inferred novel cytokine intelectin 1 (ITLN1) remain understudied in connection to
 36 CD295 polymorphisms and diabetes mellitus (DM) or a pre-diabetic state, as well as
 37 to DNA damage seen in BC. We will explore whether CD295 (ID rs6700896) and
 38 ITLN1 (rs rs952804) SNPs impact BC with or without DM, insulin resistance (IR) or
 39 obesity. Effects of ITLN1 or CD295 polymorphism(s) on DNA damage in BC were
 40 also examined. Blood samples from 170 women with BC (including 33 and 48 with
 41 DM and pre-diabetes, respectively) and from 108 age-matched women in the control
 42 group were collected. Plasma insulin, leptin, CD295, and ITLN1 levels were
 43 measured by ELISA. DNA damage was assessed using an alkaline comet assay.

44 BC cases with clinical stage T II and positive LN as well as tumor histologic grade
 45 III, presence of obesity, pre-diabetic events, DM or IR were associated with CD295
 46 rs6700986 mutant homozygous (CC) and heterozygous (CT) genotype and ITLN1
 47 rs952804 mutant heterozygous genotype (CT) ($P \leq 0.05$). Tail DNA (%) and tail
 48 moment units were significantly associated with CD295 rs6700986 CT and ITLN1
 49 rs952804 TT genotypes. C allele (CT+CC vs. TT) and T allele (TT+CT vs. CC) for
 50 CD295 rs6700986 and ITLN1 rs952804, respectively, were associated with BC risk

Hamdy and El-Shemy 2020

($P \leq 0.05$). *ITLN1* (rs952804) and *CD295* (rs6700986) SNPs should be considered as BC associated-susceptibility risk factors in obese, insulin resistant, or pre-diabetics.

Key words: *CD295*; cytokines/inflammation; breast cancer; polymorphism/mutations; *ITLN1*; obesity/Insulin resistance/Diabetes mellitus.

Graphical Abstract.

1. BACKGROUND

Breast cancer (BC) is a very common cancer (Ibrahim et al 2014, Adeloye et al 2018). BC cases that have high levels of immune cells and/or elevated levels of pro-inflammatory cytokines are anticipated to have a poor prognosis (Stender et al 2017). Adipokines are proteins secreted by adipose tissue that are involved in a wide range of processes, including insulin sensitivity (Miehle et al 2012). A large body of evidence has supported the role of adipose tissue in the regulation of insulin resistance (IR). Meanwhile, adipocytokines, which are adipocyte-derived hormones, have also been implicated in the regulation of metabolism and IR. The protein encoded by the cluster of differentiation (*CD*)295 gene belongs to a family of cytokine receptors. There are more than 50 cytokines in the adipokine family, including CD295, a class I cytokine receptor, which play roles in malignancy in obese individuals (Vona-Davis and Rose 2007). Long chain CD295 receptor type b is responsible for most of the effects mediated by CD295 (Laschober et al 2009). CD295 is known to stimulate gene transcription by activating the cytosolic JAK-STAT proteins MAPK, PI3K, and AMPK (Mahmoudi et al 2015). CD295 is also a receptor for leptin, an adipocyte-specific hormone that regulates body weight, and is involved in regulating metabolism in adipose tissues, as well as in a novel hematopoietic pathway that is required for normal lymphopoiesis. The adipocyte-inferred cytokine intelectin 1 (*ITLN1*) is a novel secretory and galactose-binding lectin that appears to have an anti-inflammatory role in both obesity (Jamshidi et al 2017) and inflammation-related diseases (Huang et al 2016), including BC. The *ITLN1* gene product omentin1 is mainly expressed in visceral adipose tissue, and was shown to inhibit inflammatory responses and mitigate IR as well as other obesity-related disorders (Du et al 2016). An immediate relationship between obesity and increased risk of BC has been

reported (Imayama et al 2013). The relationship of BC to inflammation and obesity suggests that polymorphisms in the CD295 and/or *ITLNI* genes, which both play roles in adipose tissues, could occur BC. Moreover, hyperinsulinemia actuates proliferative tissue anomalies, due to the strong anabolic impact of insulin, which stimulates DNA synthesis and cell proliferation (Boyd 2003). Increased IR promotes elevated glucose levels that can be specifically cytotoxic and pro-inflammatory (Nasiri et al., 2019), as well as oxidatively stressful, and thus could be associated with DNA damage (Ibarra-Drendall et al 2011).

This study was conducted to determine whether single nucleotide polymorphisms (SNPs) in *CD295* (ID rs6700896) and *ITLNI* (rs rs952804) confer risk for metabolic disorders (IR and/or DM) in female BC patients in Egypt. The first aim of this study was to explore how these SNPs affect BC in the presence or absence of diabetes, insulin resistance, or obesity, whereas the second aim was to examine DNA damage in these patients using a comet test to detect DNA strand breaks in individual cells from mononuclear cells isolated from blood samples (Galardi et al 2012). Realizing that no study inspected the relationship of polymorphisms in these genes with the level of DNA damage in BC cases, this will be the first main study to do this examination.

2. SUBJECTS, MATERIALS, AND METHODS

2.1. Subjects

This is a retrospective randomized single-center study, composed of patients treated with chemotherapy for inflammatory BC at a University center (National Cancer Institute (NCI), Cairo) between January 2015 and December 2015. The study protocol was approved by the ethical committees of the Faculty of Pharmacy, Ain Shams University (code number 30/7/2016-F-EBD-01-03) and the NCI, Cairo University,

Cairo, Egypt. The study was carried out in accordance with the regulations and recommendations of the Declaration of Helsinki (WMA 2013). Written informed consent was obtained from all study subjects.

2.1.1. Inclusion criteria

Females diagnosed with invasive ductal carcinoma (IDC) for the first time at age 43 or older were included. A total of 170 postmenopausal female patients aged 43-75 were selected and the median age was 53 years-old.

2.1.2. Exclusion criteria

Patients having incomplete data or histopathologic diagnosis, as well as patients with metastasis at the time of initial diagnosis were excluded. Males with BC were excluded as were BC types other than IDC. Other exclusion criteria were: previous or current history of acute or chronic viral hepatitis; malignant disease; acute infections; pituitary, adrenal, thyroid, or pancreatic disease, or evidence of any other endocrine disorders; or prolonged use of corticosteroids or sex hormones.

2.1.3. Control group

A group of 108 age-matched healthy controls (median age 53 years) with normal liver enzyme levels and no clinical or laboratory evidence of BC was recruited during routine wellness examinations.

2.1.4. Participant data

The demographic characteristics of the study subjects are summarized in Table 1a. Clinical data were obtained using medical records and original pathology reports and were compiled in an Excel database (Microsoft Corporation, Redmond, WA, USA). The following parameters were assessed: patient age, tumor size (defined as sonographic diameter (mm) on diagnosis), initial tumor stage and nodal status according to TMN classification, histologic subtype, estrogen receptor status,

progesterone status, HER2 status (a score of 0 to +1 was regarded as HER2 negative and a score of +3 as positive), grading and proliferation status as assessed by Ki-67 staining, and chemotherapy regimen (doxorubicin/trastuzumab/lapatinib). All histopathological parameters included were derived from the original pathology reports. Scoring was performed by a specialized pathologist at the Pathology Department, NCI, Cairo University, according to standardized protocols.

2.2. Blood sample collection and preparation

A 7 mL blood sample was collected from each patient into 10 mL K₃EDTA vacutainer tubes at the end of the clinical examination interview. Samples were stored at -80 °C until biochemical assessment at the Research Lab in the Biochemistry Department, Faculty of Pharmacy, Ain Shams University. One part of the sample was used for DNA extraction from the blood and was carried out using the QIAamp DNA Mini Kit protocol (QIAGEN, Inc., Santa Clarita, CA, USA). The extracted DNA was stored at -80 °C until use in SNP assays. The remaining sample was used for in comet assays.

2.2.1. Biochemical analysis

ELISA was used to determine plasma insulin, leptin, CD295, and ITLN1 levels as well as CEA, CA15.3, luteinizing hormone (LH), and follicle stimulating hormone (FSH) according to the manufacturers' instructions. Homeostasis model assessment (HOMA), a measure of IR, was calculated as: $[(\text{FBG} \times \text{fasting insulin})/22.5]$ (Mathews et al 1985). This value is regarded as a simple, inexpensive, and reliable surrogate measure of IR, whereas the HOMA of β -cell function (HOMA-B) index, computed as the product of 20 and basal insulin levels divided by the value of basal glucose concentrations minus 3.5, is accepted as a good measure of β -cell function (Wallace et al 2004).

2.3. Genetic analysis

Genotyping was performed using Assays-by-Design supplied by Applied Biosystems International (ABI) (Applied Biosystems, Foster City, CA). Reactions were performed on a 7500 ABI Sequence Detection System. The *CD295* rs6700986 polymorphism is a T/C (FWD) single-nucleotide variation on human chromosome 1:180452403, p31.3, Ancestral Allele: C. GAGAATCACTTGAAACCTAGGAGGC[T/C]AAGGTTGTGGTGAGCCGAGAT CATG, Gene: ACBD6 (GeneView), Functional Consequence: intron variant, Global MAF:T=0.4603/2305. The *ITLN1* rs952804 polymorphism is a C/T (FWD) single-nucleotide variation on human chromosome 1:160874955, q23.3, Ancestral Allele: C. CCACCTGCAGCTTTAGAAATTGGGTT[C/T]ATCTGTCTTCTCTATCACTTCTTT A, Global MAF:T=0.4335/2171. SNPs (<http://www.ncbi.nlm.nih.gov/snp/?term=>) were chosen based on a minor allele frequency that exceeded 5%.

2.3.1. Genotyping and single nucleotide polymorphism (SNP)

SNP genotyping was performed using the TaqMan® method for allele-specific detection (ABI), which involves real-time PCR amplification with fluorescence detection (Heid et al 1996). The experiments were performed using an ABI Prism® Sequence Detection System (ABI) and TaqMan® Universal PCR Master Mix (ABI) together with 20 ng genomic DNA template (10 ng/μl). Each 25 μl reaction volume contained 100 ng genomic DNA, 0.2 mM dNTPs, 20 mM Tris-HCl (pH 8.8), 10 mM KCl, 10 mM (NH₄)₂SO₄, 2 mM MgSO₄, 0.1% Triton X-100, and 1 unit *Taq* polymerase (New England BioLabs). PCR amplification conditions were as follows: an initial denaturation step at 94 °C for 5 min followed by 34 cycles of 30 sec at 94 °C; 45 sec at 60 °C and 45 sec at 72 °C; and a final elongation at 72 °C for 10 min.

After PCR amplification, we performed an endpoint plate read using an ABI StepOne Plus Real-Time PCR System.

2.4. Comet assay

Alkaline comet assays were performed according to a standard protocol (Singh et al., 1988; Comet assay kit, Trevigen). DNA migration in peripheral blood leukocytes was measured using a computer-based image analysis system (COMET IV software, Perceptive) connected to a camera (Leica DFC340 FX). The supplied software computed all major measurement parameters, including tail length, which describes the distance from the center of the nucleoid mass to the distal tail end, tail intensity (TI): the relative fluorescence intensity of the comet tail that is a measure of the percentage of DNA in the tail, and tail moment unit (TMU): essentially the product of tail length and TI.

2.5. Statistical analysis

All statistical analyses were conducted using the SPSS statistical package for Windows Version 22.0 (SPSS Software, Chicago, IL, USA). First, we tested the normal distribution of the data in which the results for continuous variables were expressed as mean $\pm$ standard deviation (SD) in addition to the median (range) for nonparametric data. To study the association between variables an odds ratio (OR) was calculated. For categorical variables, a Chi-square test was used to make comparisons between different groups. The best cutoff values for the investigated parameter(s) (FSH) were calculated from ROC curves. Genetic analyses were also conducted using unconditional logistic regression. Initially, we used univariate analyses to examine possible associations between each polymorphism and cancer grades (II and III) or T (I and II) or N (-/+), or DNA damage and associated metabolic factors (e.g., insulin, HOMA-IR, and IR). We also conducted subgroup analyses to

examine potential interactions by the levels of the pre-specified factors and the studied SNPs. Based on the findings from our population, we computed the frequencies of each allele using Hardy-Weinberg equilibrium (HWE) and online software. A likelihood ratio test was performed to test significances. Correlations were assessed using the Spearman correlation coefficient (r). Two-tailed analyses were performed, and P values ≤ 0.05 were considered statistically significant.

3. RESULTS

A total of 278 individuals were recruited for this study, including 170 females with BC, of whom 158 were insulin resistant (Table 1a). Among the BC patients, 132 were obese. Of the obese BC patients, 88 were normoglycemic, 48 were pre-diabetic and 33 had DM. The healthy control group had 108 individuals, of which 40 and 68 were lean and obese, respectively (Table 1a).

3.1. *Clinical and biological analysis of the study population*

Various anthropometric parameters, obesity and diabetes factors, and BC clinical measures, as well as plasma levels of leptin, CD295, ITLN1 were collected (Table 1a), as was information concerning the SNPs under study and DNA damage parameters for both the BC patients and the healthy controls (Table 1b). There were significant differences among the measured values between the control and BC group in terms of polymorphism frequency and DNA damage (see below; $P \leq 0.05$).

235 **Table 1a. Anthropometric parameters, obesity and diabetes factors, and breast**
236 **cancer clinical factors in breast cancer patients compared to the control group**

Parameter	Control (n=108)	BC patients (n=170)	<i>P-value</i>
Age (years)	53 (43-66)	53 (43-75)	
Insulin (μIU/mL)	8 (4.5-19)	10.6 (3.8-17.3)	0.007
FBG (mg/dL)	100 (66-144)	120 (85-224)	
HOMA-IR index	2.2 (0.81-4.9)	3.4 (0.9-6.6)	0.02
HOMA-B	0.8 (0.31-6)	0.68 (0.13-1.94)	0.03
Obese (-/+)	40/68	38/132	
IR (-/+)	50/58	12/158	
Diabetes (-/pre/+)	90/16/2	88/48/33	
Leptin (ng/mL)	7 (2-11)	15 (8-50)	<0.001
LepR (ng/mL)	22 (11-27)	20 (13-27)	0.001
ITLN1 (ng/mL)	99 (66-177)	40 (30-66)	<0.001
Ejection fraction %		64 (54-80)	
CEA (ng/mL)		4 (1-10)	
CA15.3 (U/mL)		20 (1-126)	
Ki-67		70 (15-80)	
LH (IU/L) ^a		9.9 ± 0.12	
FSH (mIU/L) ^a		24.5 ± 1.85	
Estradiol (pg/mL) ^a		27.1 ± 6.9	
Tumor clinical stage (T) (I/II)		69/101	
Lymph node status (N) (-/+)		66/104	
Metastasis (M) (-/+)		170/0	
Tumor histological grades (II/III)		141/29	
BIRAD (III/IV)		42/128	

237 Data are median (range), statistical analysis was performed using Mann–Whitney U
238 test,

239 ^a data are mean ± S.D, statistical analysis was performed using Chi-square test.

240 FBG; fasting blood glucose, HOMA-IR; homeostasis model assessment-insulin
241 resistance, CEA; carcinoembryonic antigen, CA 15.3; cancer antigen 15.3, LH;
242 luteinizing hormone, FSH; follicle stimulating hormone.

243

244

245

246

247

248 **Table 1b. Studied SNPs and DNA damage parameters of breast cancer patients**
249 **compared to the control group**

Groups(n)/ parameters	Control (n=108)	BC (n=170)	P-value
CD295 rs6700986 ^a			
Genotype			
Homozygous wild-type TT	94	36	0.04
Homozygous mutant-type CC	5	53	<0.001
Heterozygous mutant-type CT	9	81	0.007
CC+CT	14	134	<0.001
ITLN1 rs952804 ^a			
Genotype			
Homozygous wild-type CC	84	46	0.037
Homozygous mutant-type TT	15	48	0.001
Heterozygous mutant-type CT	9	76	<0.001
TT+CT	24	124	<0.001
DNA damage			
Tail intensity (%)	2 (1-4)	13 (8-19)	0.001
Tail length (µm)	0.7 (0.53-0.86)	3.5 (2.7-4.34)	0.001
Tail DNA (%)	1.3 (0.9-1.84)	3.95 (2.45-4.97)	0.02
Tail moment unit	3 (2.4-5.4)	12 (9.27-17)	0.001

250 Data are median (range); statistical analysis was performed using Mann–Whitney U
251 test,

252 ^adiscrete data are given as numbers; statistical analysis was performed using Chi-
253 square test. ITLN1; intelectin-1, CD295; cluster of differentiation 295.

254 3.2. Distribution of CD295 and ITLN1 genotypes

255 CD295 wild homozygous genotype (TT) was detected in almost all controls (94/108;
256 87%), but only 36 (21%) BC patients carried this genotype (Table 1b). Meanwhile,
257 mutant homozygous (CC) and heterozygous (CT) CD295 genotypes were seen in 53
258 (31.1%) and 81 (47.6) BC cases, respectively. For ITLN1, the wild homozygous
259 genotype (CC) was detected in the majority of the control subjects (77.7%), whereas
260 46 (43%) of BC patients carried this genotype (Table 1b). Mutant homozygous (TT)
261 and heterozygous (CT) genotypes were reported in 48 (28.2%) and 76 (44.7%) BC
262 cases, respectively.

3.3. *Distribution of the studied SNPs genotypes among the BC patient clinicopathological factors*

Stratification of the BC group according to FSH (mIU/L) values revealed that the *CD295* rs6700986 mutant homozygous (CC) and heterozygous (CT) genotype was significantly associated ($P \leq 0.05$) with BC cases that had FSH values > 25 mIU/L. A similar association was seen for BC patients who were heterozygous for the *ITLNI* rs952804 mutation (CT) (Table 2). HER2/Neu cancer cases with a +3 score had a significantly higher frequency of mutant homozygous (CC) and heterozygous (CT) *CD295* rs6700986 genotypes compared to those who had the wild homozygous (TT) genotype ($P \leq 0.05$). Similar results were also seen for *ITLNI* rs952804 mutant heterozygous cases (CT).

Tumor clinical stage T II and positive LN involvement as well as tumor histologic grade III were associated with *CD295* rs6700986 mutant homozygous (CC) and heterozygous (CT) genotypes, as well as *ITLNI* rs952804 mutant heterozygous cases (CT) ($P \leq 0.05$; Table 2).

Table 2. Distribution of CD295 SNP rs6700986 and ITLN1 SNP rs952804 genotypes among clinicopathological factors for breast cancer patients (n=170).

SNP		CD295 rs6700986				ITLN1 rs952804			
		TT	CC	CT		CC	CT	TT	
Clinicopathological factors		n (%)	n (%)	n (%)	<i>P-value***</i>	n (%)	n (%)	n (%)	<i>P-value***</i>
Breast cancer	Lt	31 (25.2)	40 (32.5)	52 (42.3)	0.035	33 (26.8)	56 (45.5)	34 (27.6)	
	Rt	5 (10.9)	12 (26.1)	29 (63)		13 (28.3)	19 (41.3)	14 (30.4)	
FSH (mIU/L)	< 25	33 (49.3)	33 (49)	68 (51)		18 (39.1)	23 (30.7)	19 (39.6)	
	> 25	3 (8.6)	19 (54.3)	13 (37)	0.014	28 (60.9)	52 (69.3)	29 (60.4)	0.016
HER2/Neu	0-1+	24 (35.3)	12 (17.6)	32 (47.1)		29 (63)	24 (32)	15 (31.3)	
	2+	4 (7.1)	21 (37.5)	31 (55.4)		7 (15.2)	31 (41.3)	18 (37.5)	
	3+	8 (17.8)	19 (42.2)	18 (40)	0.001	10 (21.7)	20 (26.7)	15 (31.3)	0.004
Tumor clinical stage (T)	I	13 (19.1)	24 (35.3)	31 (45.6)		18 (26.5)	21 (30.9)	29 (42.6)	
	II	23 (22.8)	28 (27.7)	50 (49.5)		28 (27.7)	54 (53.5)	19 (18.8)	0.002
Lymph node status (N)	-	19 (28.8)	13 (19.7)	34 (51.5)		26 (39.4)	28 (42.4)	12 (18.2)	
	+	17 (16.5)	39 (37.9)	47 (45.6)	0.024	20 (19.4)	47 (45.6)	36 (35)	0.007*
Tumor histological grade	II	33 (23.4)	45 (31.9)	63 (44.7)		41 (29.1)	59 (41.8)	41 (29.1)	
	III	3 (10.7)	7 (25)	18 (64.3)	0.032**	5 (17.9)	16 (57.1)	7 (25)	0.027

For FSH the best cutoff value (=25) was calculated by ROC curve.

* CC different from TT, ** CT different from TT, *** CT different from CC

282 ITLN1; intelectin-1, FSH; follicle stimulating hormone, CD295; cluster of differentiation 295.

3.4. *Distribution of CD295 rs6700986 and ITLN1 rs95280*

genotype variants among BC patient obesity/IR factors

The presence of obesity, IR or DM, as well as having experienced a pre-diabetic event were associated with mutant homozygous (CC) (for obesity and IR only) and heterozygous (CT) *CD295* rs6700986 genotypes ($P \leq 0.05$; Table 3). Also, obesity, pre-diabetic event and being diabetic, in addition to IR were associated with BC cases that were *ITLN1* rs952804 mutant heterozygous (CT) ($P \leq 0.05$; Table 3).

3.5. *Association between CD295 rs6700986 and ITLN1rs952804*

polymorphism and anthropometric parameters of BC patients

Mutant homozygous (CC) and heterozygous (CT) genotypes for *CD295* rs6700986 and *ITLN1* rs952804 mutant homozygous (TT) and heterozygous cases (CT) were significantly ($P \leq 0.05$) associated with higher age (median 54, 53, respectively) for both SNPs tested (Table 4). This association also occurred for BC patients who had decreased plasma CEA (ng/mL) levels, increased insulin (μ IU/mL) levels, IR, or increased plasma leptin (ng/mL) levels (Table 4).

3.6. *Relationship between studied SNPs CD295 rs6700986 and*

ITLN1 rs952804 genotypes and DNA damage parameters

Among DNA damage parameters, only tail DNA (%) and tail moment unit were significantly ($P \leq 0.05$) associated with *CD295* rs6700986 mutant heterozygous (CT) genotype and *ITLN1* rs952804 mutant homozygous (TT) genotype (Table 5).

Table 3. Distribution of genotype variants of CD295 rs6700986 and ITLN1 rs952804 SNPs among obesity/IR factors in breast cancer patients (n=170)

SNP		CD295 rs6700986				ITLN1 rs952804			
Parameters		TT n (%)	CC n (%)	CT n (%)	<i>P-value</i> *	CC n (%)	CT n (%)	TT n (%)	<i>P-value</i> ***
Obesity	Event (-)	8 (21.1)	6 (15.8)	24 (63.2)	0.05**	11 (28.9)	18 (47.4)	9 (23.7)	0.05
	Event (+)	28 (21.4)	46 (35.1)	58 (43.5)		35 (26.7)	57 (43.5)	40 (29.8)	
Diabetes	Event (-)	20 (22.7)	27 (30.7)	41 (46.6)	0.05	27 (30.7)	32 (36.4)	29 (33)	0.03
	Event (pre)	9 (18.8)	14 (29.2)	25 (52.1)		11 (22.9)	23 (47.9)	14 (29.2)	
	Event (+)	7 (21.2)	11 (33.3)	15 (45.5)		8 (24.2)	20 (60.6)	5 (15.2)	
Insulin resistance	Event (-)	10 (90.9)	1 (9.1)	0 (0)	0.01**	11 (100)	0 (0)	0 (0)	0.045
	Event (+)	26 (16.5)	51 (32.3)	81 (51.3)		35 (22.2)	75 (47.5)	48 (30.4)	

Data are number (%), significant at ($P \leq 0.05$) using Chi-square test.

* CT different from TT, ** CC different from TT, *** CT different from CC.

Table 4. Association between CD295 rs6700986 and ITLN1rs952804 polymorphisms and anthropometric parameters in breast cancer patients (n=170)

SNP Parameters	CD295 rs6700986				ITLN1 rs952804			
	TT	CC	CT	<i>P-value</i> ***	CC	CT	TT	<i>P-value</i> ***
Age (years)	50 (47-64)	54 (43-75)	53 (46-75)	0.05	50 (47-75)	53 (45-75)	54 (43-75)	0.001***
CEA (ng/mL)	4.5 (1-10)	3.5 (1-10)	4 (1-10)	0.029	9 (1-10)	4 (1-10)	3.8 (1-10)	0.003
Insulin (μIU/mL)	7.2 (3.8-16.1)	13.7 (4.9-17.3)	10.4 (5.1-15.8)	0.001	8.1 (3.8-13.1)	10.4 (6-15.8)	14.4 (9.5-17.3)	0.001
HOMA-IR	2.4 (0.9-4.5)	3.8 (1.2-6.6)	3.3 (2.5-4.3)	0.001	2.5 (0.9-3.2)	3.4 (2.7-4.1)	4 (3.4-6.6)	0.0001
Leptin (ng/mL)	15 (8-19)	16 (11-50)	15 (8-20)	0.003**	15 (8-20)	15 (8-50)	16 (11-25)	0.015**

Data are median (range), significant at $P \leq 0.05$ using Chi-square test.

* CT different from TT, ** CC different from TT, *** CT different from CC.

HOMA-IR; homeostasis model assessment-insulin resistance, ITLN1; intelectin-1, CEA; carcinoembryonic antigen, CD295; cluster of differentiation 295.

Table 5. Genotype distribution of CD295 rs6700986 and ITLN1 rs952804 SNPs relative to DNA damage parameters in breast cancer patients (n=170)

SNPs/ DNA damage	CD295 rs6700986			<i>P-value*</i>	ITLN1 rs952804			<i>P-value**</i>
	TT	CC	CT		CC	CT	TT	
Tailed (%)	13 (8-19)	13 (8-17)	13 (8-19)		13 (8-19)	13 (8-19)	13 (8-17)	
Tail length (µm)	3.8 (2.7-4.3)	3.4 (3-4.3)	3.5 (2.7-4.3)		3.6 (2.7-4.3)	3.6 (2.7-4.3)	3.5 (3-4.3)	
Tail DNA (%)	3.7 (2.5-5)	4 (2.5-5)	3.5 (2.5-5)	0.043	4 (2.5-5)	4 (2.5-5)	3.4 (2.5-5)	0.029
Tail moment unit	12.2 (9.3-17)	12.2 (10-17.1)	11.6 (9.3-17)	0.031	12.2 (10-17.1)	12.2 (10-17.1)	11 (9.3-16.1)	0.016

Data are median (range), significant at $P \leq 0.05$ using Chi-square test.

* CT different from TT, ** TT different from CC.

4. DISCUSSION

The results of our study on a population of BC patients in Egypt demonstrated that the *CD295* gene is highly polymorphic among BC patients. We found that *CD295* polymorphisms were associated with BC cases having late TN classification, as well as FSH levels > 25 mIU/L and HER2/Neu score of +3. Furthermore, BC patients who were obese, diabetic, or pre-diabetic were more likely to carry type I cytokine receptor; leptin receptor (LEP-R) *CD295* polymorphisms. Those patients who had mutant homozygous (CC) or heterozygous (CT) *CD295* rs6700986 genotypes had a higher incidence of tumor clinical stage T II, positive LN involvement, histologic grade III, obesity, pre-diabetes, IR or DM. The CD295 protein is encoded by a gene belonging to the 130-member family of glycoprotein cytokine receptors that are known to enhance gene transcription by activating cytosolic STAT proteins (Vona-Davis and Rose 2007). In addition to functioning in hemoatopoietic pathways that are required for lymphopoiesis, CD295 functions as a receptor for leptin, a hormone that acts on adipocytes to regulate body weight (Wauman et al 2017). Indeed, mutations in the gene that encodes leptin have been related to an increased frequency of obesity (Mahmoudi et al 2015). Moreover, leptin plays a role in cell growth and differentiation, as well as angiogenesis by promoting increased production of signaling molecules such as NO, VEGF, FGF2, and VEGFR2 by endothelial cells (Gonzalez et al 2006). In cancer, leptin is considered to act as both a mitogenic and migration factor in malignant cells (Choi et al 2005). In the context of BC, however, Woo et al (2006) found no significant connection between four polymorphisms in the leptin receptor gene and the risk of BC. They likewise did not observe noteworthy differences in serum leptin levels between BC patients and controls. We also examined the emerging role of *ITLN1* SNPs in BC, and found that rs952804

polymorphisms were related to BC risk factors (grade III, positive LN involvement) as well as to the presence of obesity, IR, DM, and pre-diabetes. These findings are consistent with earlier reports showing that *ITLN1* participates in immune defense and insulin-stimulated glucose uptake in human subcutaneous and omental adipocytes (Li et al 2015). In particular, BC cases that were heterozygous for the *ITLN1* rs952804 mutant (CT) were significantly associated with tumor clinical stage T II and positive LN involvement as well as tumor histologic grade III, presence of obesity, pre-diabetic event, DM and IR ($P \leq 0.05$). Relative to the adipokine vaspin, *ITLN1* levels appear to give be superior indicators of IR among obese patients in the study group by Sperling et al (2016). Obesity is an important health problem, and is positively correlated with the occurrence and mortality of BC (Lorincz and Sukumar 2006, Chu et al 2019). Moreover, obese BC patients are known to have a higher risk of LN metastasis, larger tumors, and higher death rates compared with non-obese patients (Rose and Vona-Davis 2010). These increased risks might be due to elevated estrogen levels that occur from enhanced aromatization in adipose tissue and increases in the levels of mitogenic agents such as insulin and/or IGF associated with obesity-related metabolic syndromes (DM and BC) (Erbay et al 2016). In addition to increased estrogen levels, increases in insulin levels may also contribute to the development of BC by enhancing insulin-like growth factor-I (IGF-1) receptor-mediated release of VEGF from breast tissues (Erbay et al 2016), which could couple with effects associated with increased leptin levels (Belfiore 2007). Moreover, the adverse influence of DM on the prognosis of cancer patients with malignancies is likely associated with effects of insulin on the tyrosine kinase growth receptor pathway (Belfiore 2007). Insulin, IGF-I, and hybrid IGF-I/insulin receptors, are all overexpressed in BC cells (DeCensi and Gennari 2011). As such, activation of these

receptors could up-regulate expression of insulin receptor substrate 2 that in turn activates downstream MAPK and phosphatidylinositol 3-kinase-Akt pathways (Belfiore 2007). Indeed, *in vitro* studies demonstrated that *ITLN1* increases insulin signal transduction by activating protein kinase Akt/protein kinase B signaling and enhancing insulin-stimulated glucose transport in isolated human adipocytes. Increased BC risk related to hyperinsulinemia could be attributed to a synergistic interaction between elevated free estrogen concentrations and aberrant insulin signaling. Furthermore, the ability of *ITLN1* to activate AKT, a key survival factor, could be a mechanism for *ITLN1*-mediated cell proliferation in BC (Bahadori et al 2014). This effect, together with *CD295* stimulation of gene transcription associated with activation of cytosolic JAK-STAT proteins, MAPK, PI3K, and AMPK (Mahmoudi et al 2015), may contribute to the increased frequency of *ITLN1* and *CD295* polymorphisms seen in this study. It should be noted that *ITLN1* rs952804 mutant heterozygous (CT), specifically the T allele, was related to BC risk, DNA damage and obesity, DM and IR. In addition, there was no statistically significant difference between our observations and that predicted by the Hardy-Weinberg principle for *ITLN1*, suggesting that the population was in Hardy-Weinberg equilibrium (HWE) (data not shown). Thus, the null hypothesis is *not* rejected, and we presume that the population is indeed in HWE, although additional study is needed to contrast the findings for this locus with that of another study population. There is currently no BC screening program in Egypt and in the absence of population-based-cancer registries in developing nations, including Egypt, patients with early pre-clinical illness may have been missed in our study. It is possible that polymorphisms of *CD295* or potentially *ITLN1* could contribute to variations in BC

occurrence. Nonetheless, in this study SNPs in *CD295* and *ITLN1* were related to oxidative stress/DNA damage in postmenopausal Egyptian female BC patients.

5. Conclusions. This study showed an increased risk of BC in women carrying the C allele of the *CD295* rs6700986 polymorphism and the T allele of the *ITLN1* rs952804 polymorphism. Our results suggest that these SNPs could be considered as BC-related risk factors.

RECOMMENDATIONS. *ITLN1* and *CD295* polymorphism testing could be used to assess BC susceptibility in either obese or insulin resistant, pre-diabetic patients. We therefore suggest that this high-risk BC population be screened for these SNPs.

Author contribution. Authors contributed equally to all aspects of this study, including data collection and analysis and drafting of the manuscript.

Conflict of Interest. None to Declare.

Funding. This research received no specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

6. REFERENCES

Adeloye D, Sowunmi OY, Jacobs W, et al. 2018. Estimating the incidence of breast cancer in Africa: a systematic review and meta-analysis. *J Glob Health*; 8(1):010419.

Bahadori M, Kohan L, Farzan M, Aliakbari S, Panah MM. 2014. An increased risk of breast cancer associated with Val109Asp polymorphism in omentin gene. *International Journal of Biosciences* 5(1): 429-434.

Belfiore A. 2007. The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer 13(7): 671 – 686.

431 **Boyd DB. 2003.** Insulin and Cancer. Integrative Cancer Therapies 2(4):315 – 329.

432 **Choi J-H, Park S-H, Leung PCK, and Choi K-C. 2005.** Expression of leptin
433 receptors and potential effects of leptin on the cell growth and activation of mitogen-
434 activated protein kinases in ovarian cancer cells,” e Journal of Clinical Endocrinology
435 & Metabolism 90(1):207–210.

436 **Chu DT, Phuong TNT, Tien NLB, et al. 2019.** The Effects of Adipocytes on the
437 Regulation of Breast Cancer in the Tumor Microenvironment: An
438 Update. Cells;8(8):857.

439 **DeCensi A, Gennari A. 2011.** Insulin breast cancer connection: confirmatory data set
440 the stage for better care. J Clin Oncol 29(1):7-10.

441 **Du Y, Ji Q, Cai L, Huang F, Lai Y, Liu Y, Yu J, Han B, Zhu E, Zhang J, Zhou**
442 **Y, Wang Z, Zhao Y. 2016.** Association between omentin-1 expression in human
443 epicardial adipose tissue and coronary atherosclerosis. Cardiovascular
444 Diabetology 15:90.

445 **Erbay B, Yilmaz TU, Eraldemir C, et al. 2016.** The Relationship between
446 Adiponectin and Breast Cancer. The Journal of Breast Health 12(2):67-71.

447 **Galardi F, Oakman C, Truglia MC, Cappadona S, Biggeri A, Grisotto L,**
448 **Giovannelli L, Bessi S, Giannini A, Biganzoli L, Santarpia L, Di Leo A. 2012.**
449 Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in
450 early breast cancer patients. Breast 21(3):336-42.

451 **Gonzalez RR, Cher S, Escobar M. et al. 2006.** Leptin signaling promotes the
452 growth of mammary tumors and increases the expression of vascular endothelial
453 growth factor (VEGF) and its receptor type two (VEGF-R2), e Journal of Biological
454 Chemistry 281(36): 26320–26328.

455 **Heid CA, Stevens J, Livak KJ and Williams PM. 1996.** Real time quantitative
456 PCR. *Genome Res* 6:986–994.

457 **Huang C-J, Slusher AL, Whitehurst M, Wells M, Maharaj A and Shibata Y.**
458 **2016.** The impact of acute aerobic exercise on chitinase 3-like protein 1 and
459 intelectin-1 expression in obesity. *Experimental Biology and Medicine* 241(2): 216–
460 221.

461 **Ibarra-Drendall C, Dietze EC and Seewaldt VL. 2011.** Metabolic Syndrome and
462 Breast Cancer Risk: Is There a Role for Metformin? *Curr Breast Cancer Rep* 3:142–
463 150.

464 **Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. 2014.** Cancer
465 Incidence in Egypt: Results of the National Population-Based Cancer Registry
466 Program. *Journal of Cancer Epidemiology* 2014:437971.

467 **Imayama I, Alfano CM, Neuhouser ML, et al. 2013.** Weight, inflammation, cancer-
468 related symptoms and health-related quality of life among breast cancer
469 survivors. *Breast Cancer Research and Treatment* 140(1):159–176.

470 **Jamshidi J, Ghanbari M, Asnaashari A, Jafari N, Valizadeh GA. 2017.** Omentin
471 Val109Asp polymorphism and risk of coronary artery disease. *Asian Cardiovascular*
472 *Thoracic Annals* 25(3):199-203.

473 **Laschober GT, Brunauer R, Jamnig A, Fehrer C, Greiderer B, Lepperdinger G.**
474 **2009.** Leptin receptor/CD295 is upregulated on primary human mesenchymal stem
475 cells of advancing biological age and distinctly marks the subpopulation of dying
476 cells. *Experimental Gerontology* 44(1-2):57–62.

477 **Li D, Mei H, Pu J, et al. 2015.** Intelectin 1 suppresses the growth, invasion and
478 metastasis of neuroblastoma cells through up-regulation of N-myc downstream
479 regulated gene 2. *Molecular Cancer* 14:47.

480 **Lorincz AM, Sukumar S. (2006)** Molecular links between obesity and breast cancer.
481 Endocr Relat Cancer 13:279-292.

482 **Mahmoudi R, Noori Alavicheh B, Nazer Mozaffari MA, Fararouei M,**
483 **Nikseresht M. 2015.** Polymorphisms of Leptin (-2548 G/A) and Leptin Receptor
484 (Q223R) Genes in Iranian Women with Breast Cancer. International Journal of
485 Genomics 2015:132720.

486 **Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner**
487 **RC. 1985.** Homeostasis model assessment: insulin resistance and beta cell function
488 from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–
489 419.

490 **Miehle K, Stepan H and Fasshaauer M. 2012.** Leptin, adiponectin, and other
491 adipokines in gestational diabetes mellitus and pre-eclampsia. ClinEndocrinolo. 76:2-
492 11.

493 **Nasiri AR, Rodrigues MR, Li Z, Leitner BP, Perry RJ. 2019.** SGLT2 inhibition
494 slows tumor growth in mice by reversing hyperinsulinemia. Cancer Metab.;7:10.

495 **Rose DP and Vona-Davis L. 2010.** Interaction between menopausal status and
496 obesity in affecting breast cancer risk. Maturitas 66:33-38.

497 **Singh NP, McCoy MT, Tice RR, Schneider EL. 1988.** A simple technique for
498 quantitation of low levels of DNA damage in individual cells. Experimental Cell
499 Research 175(1):184-191.

500 **Sperling M, Grzelak T, Pelczyńska M, Jasinska P, Bogdanski P, Pupek-Musialik**
501 **D, Czyzewska K. 2016.** Concentrations of omentin and vaspin versus insulin
502 resistance in obese individuals. Biomed Pharmacother 83:542-547.

503 **Stender JD, Nwachukwu JC, Kastrati I, Kim Y, Strid T, Yakir M, Srinivasan S,**
504 **Nowak J, Izard T, Rangarajan ES, Carlson KE, Katzenellenbogen JA, Yao XQ,**

Hamdy and El-Shemy 2020

505 **Grant BJ, Leong HS, Lin CY, Frasor J, Nettles KW, Glass CK. 2017.** Structural
506 and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in
507 Human Breast Cancer Cells. *Mol Cell*. 65(6):1122-1135.e5

508 **Vona-Davis L. and Rose DP. 2007.** Adipokines as endocrine, paracrine, and
509 autocrine factors in breast cancer risk and progression. *Endocrine-Related Cancer*
510 14(2):189–206.

511 **Wallace TM, Levy JC, Matthews DR. 2004.** Use and Abuse of HOMA Modeling.
512 *Diabetes Care* 27(6):1487-1495.

513 **Wautman J, Zabeau L, Tavernier J. 2017.** The Leptin Receptor Complex: Heavier
514 Than Expected?. *Front Endocrinol (Lausanne)*;8:30.

515 **WMA. 2013.** 64th World Medical Association General Assembly, Fortaleza, Brazil,
516 October 2013. <http://www.wma.net/en/30publications/10policies/b3>.

517 **Woo H-Y, Park H, Ki C-S, Park YL, and Bae WG. 2006.** Relationships among
518 serum leptin, leptin receptor gene poly- morphisms, and breast cancer in Korea,
519 *Cancer Letters* 237(1):137–142.